Australia's most trusted
source of pharma news
Posted 25 November 2021 AM
Australian researchers have found a common medication used to treat reflux, heart burn and ulcers could lessen the effectiveness of lung cancer immunotherapy drugs.
A study by Flinders University, published in Nature's British Journal of Cancer, investigated the impact of proton pump inhibitors (PPIs) on patients undergoing treatment for non-small-cell lung cancer, the most common type of lung cancer, accounting for 85 per cent of cases.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.